AdAlta Limited Seeks ASX Quotation for 37.5 Million Shares and 168.75 Million Options Issued as Lead Manager Fees

AdAlta Completes Lead Manager Fee Settlement with Quotation Application Following May 2026 Placement

On 2 July 2026, AdAlta Limited submitted an Appendix 2A to the ASX requesting quotation of new shares and options issued as non-cash lead manager fees tied to the placement announced on 4 May 2026. The Appendix 2A is the formal step for a listed entity to enable trading of newly issued securities, finalizing the process initiated by the original Appendix 3B lodged in May.

The update confirms no further securities are pending issuance to complete the transactions referenced in the original Appendix 3B, indicating this quotation application finalizes the obligations from that capital raise. For investors and market participants, this filing concludes the administrative lifecycle of the May 2026 placement, with all related securities, including those issued as fees, now entering the quoted market.

Details of the 37.5 Million New Shares Issued to Lead Manager

The first tranche applied for quotation consists of 37,500,000 ordinary fully paid shares (ticker: 1AD), issued on 2 July 2026. These shares were issued as part of the lead manager's fee, representing 6% of the gross proceeds from the placement, settled in shares on identical terms to those issued to placement participants. The company disclosed an estimated value of $0.004 per share for this tranche.

Issuing lead manager fees in shares rather than cash is a strategy often employed by smaller listed companies to conserve working capital while remunerating capital markets services. Although these shares increase the total share count and dilute existing holdings proportionally, they do not generate new cash for the company. The total cash-equivalent value of this share tranche was not separately aggregated in the company update.

Breakdown of 168.75 Million Options Expiring June 2028 into Two Sub-Tranches

The options portion of the lead manager fee exceeds the share count and totals 168,750,000 options expiring 3 June 2028 (ticker: 1ADO), split into two sub-tranches. The first sub-tranche includes 12,500,000 options described as lead manager fees of 6% of gross proceeds, valued at $0.002 per option. The second, larger sub-tranche comprises 156,250,000 options labeled "Lead Manager Options as announced in Placement on 4 May 2026," also valued at $0.002 per option.

Both sub-tranches share the 3 June 2028 expiry and will be quoted under the single 1ADO code. Consequently, all 168,750,000 newly listed options will trade alongside existing 1ADO securities. The exercise price and other terms were not restated in this application; investors should consult the original 4 May 2026 placement announcement for full details.

AdAlta's Quoted Share Capital Surpasses 3 Billion Following Quotation

According to Part 4 of the Appendix 2A, post-quotation AdAlta's total quoted ordinary fully paid shares will be 3,013,419,019, reflecting the inclusion of the 37,500,000 new shares. This places AdAlta among micro-cap and small-cap biotech companies that have expanded share counts through successive capital raises and fee settlements.

A share count above three billion is notable for both retail and institutional investors. While share count alone does not determine value—which depends on the company's assets, pipeline progress, and market capitalization—it impacts liquidity, dilution potential from future raises, and the per-share effect of milestones. The immediate share price impact of this quotation was not evident from public information.

Quoted 1ADO Options Exceed One Billion After New Listing

With the addition of 168,750,000 new 1ADO options, the total quoted options in the 1ADO class expiring 3 June 2028 will reach 1,017,651,397, surpassing one billion. This reflects options issued to placement participants and those granted as lead manager fees. Such a large options pool represents a significant potential source of future share issuance upon exercise, which may dilute existing shareholders depending on the exercise price relative to the prevailing market price at exercise time.

Holders have approximately two years from this application date to exercise options expiring 3 June 2028. Should the share price exceed the exercise price before expiry, holders would be incentivized to convert options into ordinary shares, increasing the share count and potentially raising additional capital. The exercise price was not restated here; investors should refer to the original placement terms.

Unquoted Securities Including Performance Rights and Additional Options Remain on Register

Beyond quoted securities, Part 4.2 of the application lists unquoted securities: 13,794,695 options expiring on various dates and prices (ticker: 1ADAD), and 1,041,788 performance rights expiring 6 December 2028 (ticker: 1ADAL). These unquoted securities, often issued to employees, directors, or other stakeholders under incentive plans or service agreements, are not tradable until quoted.

Performance rights like the 1ADAL securities are common long-term incentives in Australian listed companies. They typically vest upon meeting performance or service conditions and convert into ordinary shares. The modest number of performance rights—just over one million—suggests targeting senior management or key personnel, though the company update does not specify vesting conditions.

Context: Placement on 4 May 2026 Established Terms for Fee Securities

The securities now applied for quotation originate from the placement announced on 4 May 2026. At that time, AdAlta lodged an Appendix 3B notifying the market of a proposed securities issue. The lead manager was entitled to a fee of 6% of gross proceeds, agreed to be settled in shares and options on the same terms as placement participants rather than cash.

This scrip-based fee payment is common among smaller listed companies, especially pre-revenue or early-revenue biotech firms. It aligns the lead manager’s interests with the company’s by tying fee value to future share price performance. The gross proceeds from the original placement were not restated here, so the total dollar value of the lead manager fee cannot be independently calculated from this filing alone.

Implications of Completing This Capital Transaction for AdAlta’s Registry Activity

Part 2.3a.2 of the Appendix 2A confirms no further securities issuances remain to complete the original Appendix 3B transactions, marking full discharge of obligations from the May 2026 placement, including lead manager fees. This concludes the placement cycle from a registry and compliance standpoint.

For investors tracking AdAlta’s capital activity, this filing closes a recent chapter in the company’s corporate finance. Upcoming milestones to watch include updates on clinical pipeline progress, operational activities, or financial status that may prompt further capital market activity. Given the options pool now exceeds one billion 1ADO options, potential future capital inflows from option exercises will also be of interest to market participants monitoring funding runway and cash position.

AdAlta’s Biotech Focus and Capital Markets Role in Pipeline Funding

AdAlta Limited is an Australian biotech company focused on developing i-body technology—a proprietary platform derived from shark antibody domains—to create novel therapeutics addressing diseases with significant unmet medical need. Capital market transactions, including placements and associated securities issuances reflected here, are routine and essential for funding pre-revenue biotech companies investing in research and development ahead of commercialisation.

The completion of lead manager fee settlement and quotation of these securities do not indicate any change in AdAlta’s strategic direction or clinical timeline. Rather, they reflect ongoing administrative and corporate governance efforts to comply with ASX listing rules and maintain transparency in the capital structure. Investors will look to the company’s next substantive update—on pipeline, partnerships, or financial position—for insights into deployment of proceeds from the May 2026 placement.